IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.
Saved in:
| Title: | IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities. |
|---|---|
| Authors: | Cazzola M; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. mario.cazzola@uniroma2.it., Page CP; Institute of Pharmaceutical Science, King's College London, London, UK., Matera MG; Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy. |
| Source: | Lung [Lung] 2026 May 22; Vol. 204 (1). Date of Electronic Publication: 2026 May 22. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Springer Verlag Country of Publication: United States NLM ID: 7701875 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1750 (Electronic) Linking ISSN: 03412040 NLM ISO Abbreviation: Lung Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
